InnoCare Pharma Initiates ICP-538 Clinical Trial
Analysis based on 10 articles · First reported Feb 09, 2026 · Last updated Mar 16, 2026
The initiation of a clinical trial for ICP-538 by InnoCare Pharma is a positive development for the biotechnology and pharmaceutical sectors, particularly in the autoimmune disease treatment market. This could lead to increased investor confidence in InnoCare Pharma and potentially other companies developing novel therapies.
InnoCare Pharma announced the dosing of the first healthy volunteer in a clinical trial for ICP-538 in China. ICP-538 is a novel, orally administered molecular glue degrader targeting VAV1, a key protein in T-cell and B-cell receptors. This is the first VAV1 degrader approved for clinical trials in China and the second globally. The drug is being developed for autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Preclinical studies showed ICP-538 induces deep degradation of VAV1, reducing cytokines associated with immune-mediated diseases. Dr. Jasmine Cui, CEO of InnoCare Pharma, highlighted the therapy's advantages in target selectivity, multiple mechanisms of action, and high efficacy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard